PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXEDAS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)65190-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)65190-X/fulltext
Title :
PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXEDAS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65190-X&doi=10.1016/S1098-3015(10)65190-X
First page :
Section Title :
Open access? :
No
Section Order :
351